Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with LDRT and SBRT in advanced cancers with peritoneal metastases
NCT06940921Phase 2Active, not recruiting
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric cancer (GC), colorectal cancer (CRC) and ovarian cancer. Primary endpoint: Peritoneal response rate. Started Mar 2025; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)ovarian cancer
Beyond the preview
Go deeper on NCT06940921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940921.